Team Archive - Page 2 of 3 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes
Team Archive - Page 2 of 3 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes
  • Our Company
    • Presentation
    • Management Team
    • Board of directors
    • Scientific Advisory Board
    • Contact
  • Products
    • Tedopi®
    • OSE-279
    • Lusvertikimab (OSE-127)
    • Pegrizeprument (FR104)
    • BI 770371
    • ABBV-230
    • CLEC-1
  • Research & Development
    • Scientific publications
  • Investors
    • Press Releases
    • Letter to Shareholders
    • Newsletters
    • Q & A
    • Financial documents
    • General Shareholders’ meetings
    • Regulated information
  • Partnerships
    • Pharma partnerships
    • Clinical partnerships
    • Academic and public Partnerships
  • News
    • Our videos
    • Agenda
    • Press Releases
  • Contact
en
  • fr

Projects Archives

December 2024

Fiona Olivier

August 2024

Thomas Gidoin

June 2023

Jean-Jacques A.P. Mention, PhD

May 2023

Silvia Comis, MD

June 2022

Jennifer Wargo, MD, M.M.Sc

June 2022

Charles N. Serhan, PhD, DSc

June 2022

Miriam Merad, MD, PhD

June 2022

Bernard Malissen, PhD

June 2022

Sophie Brouard, PhD

June 2022

Wolf-Hervé Fridman, MD

  • Précédent
  • 1
  • 2
  • 3
  • Suivant

Head Office

22, boulevard Benoni Goullin
44200 Nantes – France

Tel : +33 (0)2 28 29 10 10

Email : contact@ose-immuno.com

Paris Office

10, place de Catalogne
75014 Paris – France

Tel : +33 (0)1 43 29 78 57

Fax : +33 (0)1 42 03 04 16

Our Company
Products
Investors
Agenda
Research & Development
Partnerships
Press Releases
Follow us
©2021 ose-immuno
Financial documents
Legal information and Personal data protection policy
Site internet créé par Adveris